Table 3.

Summary of HER expression in primary and corresponding metastatic lesions in CRC patients treated with anti-EGFR cetuximab.

Case	Sex	Age	Type of Metastasis	wtEGFR 1° Met		HER2 1° Met		HER3 1° Met		HER4 1° Met		Overall Change in Expression	Response
1	Female	64	Metachronous	−ve	−ve	−ve	−ve	+ve	+ve	−ve	+ve	Yes	Yes
2	Female	52	Metachronous	+ve	−ve	−ve	−ve	+ve	−ve	−ve	+ve	Yes	Yes
3	Male	52	Synchronous	−ve	−ve	−ve	−ve	+ve	+ve	+ve	+ve	No	Yes
4	Male	60	Synchronous	+ve	+ve	+ve	−ve	+ve	+ve	+ve	−ve	Yes	No
5	Male	88	Metachronous	+ve	−ve	−ve	−ve	+ve	+ve	+ve	−ve	Yes	No
6	Male	61	Metachronous	−ve	−ve	−ve	−ve	+ve	+ve	+ve	−ve	Yes	Yes
7	Female	49	Synchronous	−ve	+ve	−ve	+ve	+ve	+ve	+ve	+ve	Yes	No
8	Female	69	Metachronous	−ve	−ve	−ve	−ve	+ve	+ve	+ve	+ve	No	No
9	Male	65	Metachronous	−ve	+ve	−ve	−ve	+ve	+ve	+ve	−ve	Yes	No
10	Female	50	Metachronous	−ve	−ve	−ve	−ve	+ve	+ve	+ve	+ve	No	No
11	Male	56	Metachronous	+ve	−ve	−ve	−ve	+ve	+ve	+ve	−ve	Yes	Yes
12	Male	70	Synchronous	+ve	+ve	−ve	−ve	+ve	+ve	+ve	+ve	No	Yes
13	Female	76	Metachronous	−ve	−ve	−ve	−ve	+ve	+ve	+ve	+ve	No	Yes
14	Male	62	Synchronous	+ve	−ve	+ve	−ve	+ve	+ve	−ve	+ve	Yes	Yes
15	Female	58	Metachronous	−ve	+ve	−ve	+ve	+ve	+ve	−ve	+ve	Yes	Yes
16	Male	65	Synchronous	+ve	+ve	−ve	−ve	+ve	+ve	+ve	+ve	No	Yes
17	Male	69	Metachronous	+ve	−ve	−ve	−ve	+ve	+ve	+ve	−ve	Yes	Yes
18	Male	74	Metachronous	−ve	−ve	−ve	−ve	+ve	+ve	−ve	+ve	Yes	Yes
19	Male	69	Metachronous	+ve	−ve	−ve	−ve	−ve	+ve	+ve	+ve	Yes	Yes
20	Male	35	Synchronous	−ve	−ve	−ve	−ve	+ve	−ve	+ve	+ve	Yes	No
21	Male	34	Metachronous	−ve	+ve	−ve	−ve	+ve	+ve	+ve	+ve	Yes	Yes